Study on How Residual Lipid and Inflammation Risks Affect Heart Artery Plaque Growth in Coronary Heart Disease Patients Under Intensive Lipid-Lowering Treatment

What this Trial Is About

Researchers are investigating coronary heart disease CHD patients who receive intensive lipid-lowering therapy but still show progression of coronary plaque. The study aims to better understand how leftover lipid and inflammatory risks contribute to plaque growth. This research focuses on non-target lesions near treated areas in the heart and uses intravascular ultrasound IVUS to closely examine plaque changes. The study is observational and sponsored by Shanghai Zhongshan Hospital. The study will enroll CHD patients who have undergone successful percutaneous coronary intervention PCI on target lesions. It will observe non-target lesions near the treated site, which have specific narrowing and anatomical markers. Researchers will collect detailed data on cholesterol and inflammatory markers such as CRP, SAA, TNF-, IL-6, MCP-1, Lp-PLA2, PCSK-9, and Lpa to assess their impact on plaque progression during intensive lipid-lowering therapy. Participants will be followed for 9 to 12 months after PCI to monitor coronary plaque progression using imaging and lab tests. The study also tracks carotid plaque progression as a secondary outcome. Data collection includes comprehensive clinical and laboratory assessments to evaluate residual risk factors. The total duration involves regular follow-up visits to monitor changes and ensure good compliance, aiming to provide new insights into residual risks under intensive lipid control.

REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease